Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

NCT07030140 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma
Hilar Cholangiocarcinoma
Bile Duct Cancer

Interventions

RADIATION: Stereotactic Body Radiotherapy (SBRT)
DRUG: Tislelizumab
DRUG: Gemcitabine
DRUG: Cisplatin or Oxaliplatin

Sponsor

Jinbo Yue